Journal article icon

Journal article

Dupilumab efficacy and safety in moderate-to-severe uncontrolled Asthma

Abstract:

Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and safety in patients with uncontrolled asthma.We randomly assigned 1902 patients 12 years of age or older with uncontrolled asthma in a 2:2:1:1 ratio to receive add-on subcutaneous dupilumab at a dose of 200 or 300 mg every 2 weeks or matched-volume placebos for 52 weeks. The primary end points were the annualized rate of severe a...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's Version

Actions


Access Document


Files:
Publisher copy:
10.1056/nejmoa1804092

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDM
Oxford college:
St Edmund Hall
ORCID:
0000-0002-4288-5973
Maspero, J More by this author
Expand authors...
Publisher:
Massachusetts Medical Society Publisher's website
Journal:
New England Journal of Medicine Journal website
Volume:
378
Issue:
26
Pages:
2486-2496
Publication date:
2018-06-28
Acceptance date:
2018-04-26
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Pubs id:
pubs:854634
URN:
uri:0e775ca3-54bd-447e-b4ca-fe0b9000cd2d
UUID:
uuid:0e775ca3-54bd-447e-b4ca-fe0b9000cd2d
Local pid:
pubs:854634

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP